Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir + MK-8507 once-weekly in HIV-1 suppressed adults
NCT04564547Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of islatravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Mar 2021; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04564547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564547.